Insider · CIK 0001422772
Helen Susan Kim
Files at PRTA (PROTHENA CORP PUBLIC LTD CO), AKTS (Aktis Oncology, Inc.). First filing Jan 12, 2026, latest Jan 12, 2026.
In brief
Helen Susan Kim files SEC Form 4 as director and 10% owner at AKTS (Aktis Oncology, Inc.), and also at PRTA (PROTHENA CORP PUBLIC LTD CO). Since Jan 12, 2026, Helen Susan Kim has reported 1 open-market buy worth $15M and 0 open-market sells worth $0, the latest filed on Jan 12, 2026.
A track record needs three past buys with six months of prices behind them; Helen Susan Kim has 0, so none is measured yet.
The newest scored trade: bought $15M of AKTS on Jan 12, 2026, filed Jan 12, 2026, scored 68 (notable). In the last 12 months: 1 buy worth $15M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKTS: Aktis Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 68Notable | Aktis Oncology, Inc. | $15M 835,000 shares | +17% | 0% from low-3% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +4,859,370 | - | - | 4,859,370 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +812,455 | $18.00 | $15M | 5,671,825 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +134,842 | - | - | 134,842 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +22,545 | $18.00 | $406k | 157,387 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -14,838,250 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -411,750 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -3,648,750 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -101,250 | $0.00 | $0 | 0 | Jan 12, 2026 |
| May 14, 2025 | PRTA PROTHENA CORP PUBLIC LTD CO | AGrant or award Stock Option (Right to Buy)derivative | +20,183 | $0.00 | $0 | 20,183 | May 16, 2025 |
| May 15, 2024 | PRTA PROTHENA CORP PUBLIC LTD CO | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | May 17, 2024 |
Questions about Helen Susan Kim
Answered from the filings on this page, as of the latest one.
Is Helen Susan Kim buying or selling?
In the last 12 months Helen Susan Kim reported 1 open-market buy worth $15M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $15M of AKTS on Jan 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Helen Susan Kim's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Helen Susan Kim has 0.
Where does Helen Susan Kim file Form 4?
Helen Susan Kim has filed Form 4 at AKTS (Aktis Oncology, Inc.); PRTA (PROTHENA CORP PUBLIC LTD CO). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.